Huntington disease: natural history, biomarkers and prospects for therapeutics

Christopher A. Ross,Elizabeth H. Aylward,Edward J. Wild,Douglas R. Langbehn,Jeffrey D. Long,John H. Warner,Rachael I. Scahill,Blair R. Leavitt,Julie C. Stout,Jane S. Paulsen,Ralf Reilmann,Paul G. Unschuld,Alice Wexler,Russell L. Margolis,Sarah J. Tabrizi

DOI: https://doi.org/10.1038/nrneurol.2014.24

IF: 38.1

2014-03-11

Nature Reviews Neurology

Abstract:Key PointsNo disease-modifying treatments are currently available for Huntington disease (HD), but clinical trials of potential compounds are imminent; identification of suitable biomarkers to assess therapeutic efficacy is a research priorityQuantifiable measures of patient function, including motor and cognitive assessments, have shown disease-related change in early HD but still lack sensitivity in premanifest cohortsStructural imaging measures such as striatal atrophy show the largest effect sizes both cross-sectionally and longitudinally, and have the potential to track disease progression even in the premanifest periodFunctional MRI and magnetic resonance spectroscopy are also sensitive for detecting change, but have not yet been well-validated longitudinallyPET imaging is quantitative and shows sensitivity to early premanifest disease, and may be useful longitudinally, but has the disadvantage of being expensive and complexBiochemical assays of relevant molecules provide a more direct reflection of disease mechanisms; such measures have not been fully validated, and future work will focus on their development

clinical neurology